

Philip Quirke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4118218/publications.pdf>

Version: 2024-02-01

204
papers

26,903
citations

13827

67
h-index

5965

160
g-index

207
all docs

207
docs citations

207
times ranked

18721
citing authors

#	ARTICLE	IF	CITATIONS
1	FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. <i>Journal of Clinical Pathology</i> , 2023, 76, 548-554.	1.0	1
2	Weakly supervised annotation-free cancer detection and prediction of genotype in routine histopathology. <i>Journal of Pathology</i> , 2022, 256, 50-60.	2.1	48
3	Improving the management of early colorectal cancers (eCRC) by using quantitative markers to predict lymph node involvement and thus the need for major resection of pT1 cancers. <i>Journal of Clinical Pathology</i> , 2022, 75, 545-550.	1.0	5
4	Deep learning identifies inflamed fat as a risk factor for lymph node metastasis in early colorectal cancer. <i>Journal of Pathology</i> , 2022, 256, 269-281.	2.1	39
5	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. <i>Clinical Trials</i> , 2022, 19, 146-157.	0.7	7
6	Swarm learning for decentralized artificial intelligence in cancer histopathology. <i>Nature Medicine</i> , 2022, 28, 1232-1239.	15.2	77
7	The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3540-3540.	0.8	0
8	STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3502-3502.	0.8	9
9	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. <i>Gut</i> , 2021, 70, 544-554.	6.1	148
10	Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 92-105.	3.7	90
11	Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: Can a regional intervention promote national change?. <i>International Journal of Cancer</i> , 2021, 148, 845-856.	2.3	10
12	Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 111-111.	0.8	1
13	Deep learning detects genetic alterations in cancer histology generated by adversarial networks. <i>Journal of Pathology</i> , 2021, 254, 70-79.	2.1	31
14	The colorectal cancer-associated faecal microbiome of developing countries resembles that of developed countries. <i>Genome Medicine</i> , 2021, 13, 27.	3.6	25
15	Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy. <i>Clinical Cancer Research</i> , 2021, 27, 2246-2254.	3.2	18
16	What is the Role of the Neutrophil: Lymphocyte Ratio in Colorectal Cancer?. <i>Turkish Journal of Colorectal Disease</i> , 2021, 31, 1-12.	0.2	2
17	Artificial Intelligence-Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3422-3431.	3.2	10
18	Luminal Bioavailability of Orally Administered ω -3 PUFAs in the Distal Small Intestine, and Associated Changes to the Ileal Microbiome, in Humans with a Temporary Ileostomy. <i>Journal of Nutrition</i> , 2021, 151, 2142-2152.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.. Journal of Clinical Oncology, 2021, 39, 3504-3504.	0.8	1
20	Lynch syndrome screening in colorectal cancer: results of a prospective 2â€year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2â€million population. Histopathology, 2021, 79, 690-699.	1.6	9
21	Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer, 2021, 125, 1080-1088.	2.9	10
22	Characterisation of dysplastic liver nodules using lowâ€pass <sc>DNA</sc> sequencing and detection of chromosome armâ€level abnormalities in bloodâ€derived cellâ€free <sc>DNA</sc>. Journal of Pathology, 2021, 255, 30-40.	2.1	4
23	Inhibition of WEE1 Is Effective in<i>TP53</i>- and<i>RAS</i>-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 2021, 39, 3705-3715.	0.8	51
24	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology, 2021, 39, 3693-3704.	0.8	19
25	Prognostic and Predictive Value of Tumor Budding in Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 256-264.	1.0	9
26	Influence of age on surgical treatment and postoperative outcomes of patients with colorectal cancer in Denmark and Yorkshire, England. Colorectal Disease, 2021, 23, 3152-3161.	0.7	7
27	Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 2021, 3, e654-e664.	5.9	69
28	Quality of Surgery. , 2021, , 279-295.		0
29	Deep learning for the detection of microsatellite instability from histology images in colorectal cancer: A systematic literature review. Immunoinformatics, 2021, 3-4, 100008.	1.2	21
30	The sigmoid take-off: An anatomical imaging definition of the rectum validated on specimen analysis. European Journal of Surgical Oncology, 2020, 46, 1668-1672.	0.5	20
31	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. British Journal of Cancer, 2020, 123, 1280-1288.	2.9	45
32	A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Molecular Oncology, 2020, 14, 2384-2402.	2.1	71
33	Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. Gastroenterology, 2020, 159, 1406-1416.e11.	0.6	209
34	Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature, 2020, 580, 269-273.	18.7	587
35	What factors determine specimen quality in colon cancer surgery? A cohort study. International Journal of Colorectal Disease, 2020, 35, 869-880.	1.0	4
36	Outcome measures in multimodal rectal cancer trials. Lancet Oncology, The, 2020, 21, e252-e264.	5.1	56

#	ARTICLE	IF	CITATIONS
37	Confirmation that somatic mutations of beta α 2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial. <i>Histopathology</i> , 2019, 75, 236-246.	1.6	15
38	Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT. <i>Efficacy and Mechanism Evaluation</i> , 2019, 6, 1-140.	0.9	27
39	No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1597-1605.	0.9	20
40	Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil results from the QUASAR trial of colorectal cancer. <i>Histopathology</i> , 2018, 72, 391-404.	1.6	16
41	Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 564.	3.4	19
42	A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. <i>Gut</i> , 2018, 67, 1974-1983.	6.1	332
43	Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 3 randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 162-171.	3.7	47
44	A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. <i>British Journal of Cancer</i> , 2018, 119, 697-706.	2.9	26
45	Colon cancer surgery: pathological quality control is essential for optimal outcomes. <i>Colorectal Disease</i> , 2018, 20, 34-35.	0.7	5
46	Reply to. <i>Annals of Surgery</i> , 2017, 266, e116-e118.	2.1	1
47	Challenging diagnostic issues in adenomatous polyps with epithelial misplacement in bowel cancer screening: 5 years experience of the Bowel Cancer Screening Programme Expert Board. <i>Histopathology</i> , 2017, 70, 466-472.	1.6	19
48	Examining the potential use and long-term stability of guaiac faecal occult blood test cards for microbial DNA 16S rRNA sequencing. <i>Journal of Clinical Pathology</i> , 2017, 70, 600-606.	1.0	16
49	Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. <i>Modern Pathology</i> , 2017, 30, 1299-1311.	2.9	652
50	Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Staging – A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 1119-1127.	0.8	166
51	Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1569.	3.8	891
52	Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. <i>British Journal of Cancer</i> , 2017, 117, 1286-1294.	2.9	22
53	A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 394.	0.7	72
54	Can we save the rectum by watchful waiting or transanal microsurgery following (chemo) radiotherapy versus total mesorectal excision for early rectal cancer (STAR-TREC study)? protocol for a multicentre, randomised feasibility study. <i>BMJ Open</i> , 2017, 7, e019474.	0.8	87

#	ARTICLE	IF	CITATIONS
55	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 63140-63154.	0.8	19
56	Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse. <i>International Journal of Molecular Sciences</i> , 2016, 17, 598.	1.8	10
57	Protocol for a multicentre randomised feasibility trial evaluating early Surgery Alone In LOw Rectal cancer (SAILOR). <i>BMJ Open</i> , 2016, 6, e012496.	0.8	4
58	Reply to D.J. Sargent et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3713-3714.	0.8	0
59	Incorporating Local and Global Context for Better Automated Analysis of Colorectal Cancer on Digital Pathology Slides. <i>Procedia Computer Science</i> , 2016, 90, 125-131.	1.2	7
60	Significant Individual Variation Between Pathologists in the Evaluation of Colon Cancer Specimens After Complete Mesocolic Excision. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 953-961.	0.7	24
61	A retrospective observational study of length of stay in hospital after colorectal cancer surgery in England' (1998â€“2010). <i>Medicine (United States)</i> , 2016, 95, e5064.	0.4	27
62	Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model. <i>Annals of Surgery</i> , 2016, 263, 751-760.	2.1	243
63	<scp>HER2</scp> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <scp>QUASAR</scp>, <scp>FOCUS</scp> and <scp>PICCOLO</scp> colorectal cancer trials. <i>Journal of Pathology</i> , 2016, 238, 562-570.	2.1	185
64	Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With<i>RAS</i>Wild-Type Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2016, 2, 633.	3.4	79
65	Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1297-1299.	0.8	65
66	The Design and Evaluation of Interfaces for Navigating Gigapixel Images in Digital Pathology. <i>ACM Transactions on Computer-Human Interaction</i> , 2016, 23, 1-29.	4.6	13
67	Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1922-1931.	3.2	30
68	Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. <i>Journal of Clinical Pathology</i> , 2016, 69, 35-41.	1.0	23
69	Next Generation intraoperative Lymph node staging for Stratified colon cancer surgery (GLiSten): a multicentre, multinational feasibility study of fluorescence in predicting lymph node-positive disease. <i>Efficacy and Mechanism Evaluation</i> , 2016, 3, 1-122.	0.9	3
70	Performance and interaction behaviour during visual search on large, high-resolution displays. <i>Information Visualization</i> , 2015, 14, 137-147.	1.2	12
71	The D Prefix. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 613-616.	0.7	4
72	A Retrospective Observational Study of the Relationship between Single Nucleotide Polymorphisms Associated with the Risk of Developing Colorectal Cancer and Survival. <i>PLoS ONE</i> , 2015, 10, e0117816.	1.1	10

#	ARTICLE	IF	CITATIONS
73	Quality of Surgery. , 2015, , 227-242.		0
74	Quality of surgery: has the time come for colon cancer?. Lancet Oncology, The, 2015, 16, 121-122.	5.1	16
75	New insights into the lymphovascular microanatomy of the colon and the risk of metastases in pT1 colorectal cancer obtained with quantitative methods and three-dimensional digital reconstruction. Histopathology, 2015, 67, 167-175.	1.6	13
76	The correlation between endoscopic and histopathological measurements in colorectal polyps. Histopathology, 2015, 66, 485-490.	1.6	11
77	Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling. BMC Medical Genomics, 2015, 8, 5.	0.7	84
78	Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 755-773.	1.3	120
79	Area of Submucosal Invasion and Width of Invasion Predicts Lymph Node Metastasis in pT1 Colorectal Cancers. Diseases of the Colon and Rectum, 2015, 58, 393-400.	0.7	62
80	Pathologic Processing of the Total Mesorectal Excision. Clinics in Colon and Rectal Surgery, 2015, 28, 043-052.	0.5	33
81	Secrets from the microbiome: molecular biology meets microbiology meets histopathology meets clinical biochemistry. Annals of Clinical Biochemistry, 2015, 52, 687-689.	0.8	0
82	Prospector: A web-based tool for rapid acquisition of gold standard data for pathology research and image analysis. Journal of Pathology Informatics, 2015, 6, 21.	0.8	4
83	Reply to C. Zhuang et al. Journal of Clinical Oncology, 2014, 32, 4022-4022.	0.8	2
84	Pathology is a necessary and informative tool in oncology clinical trials. Journal of Pathology, 2014, 232, 185-189.	2.1	17
85	The English National Low Rectal Cancer Development Programme: key messages and future perspectives. Colorectal Disease, 2014, 16, 173-178.	0.7	61
86	Quality of Surgery for Stage III Colon Cancer: Comparison Between England, Germany, and Japan. Annals of Surgical Oncology, 2014, 21, 398-404.	0.7	74
87	EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. European Journal of Cancer, 2014, 50, 1.e1-1.e34.	1.3	349
88	Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study. Journal of Clinical Oncology, 2014, 32, 34-43.	0.8	477
89	Response. Journal of the National Cancer Institute, 2014, 106, .	3.0	0
90	Multicenter Randomized Controlled Trial of Conventional Versus Laparoscopic Surgery for Colorectal Cancer Within an Enhanced Recovery Programme: EnROL. Journal of Clinical Oncology, 2014, 32, 1804-1811.	0.8	170

#	ARTICLE	IF	CITATIONS
91	Detection of somatic mutations in tumors using unaligned clonal sequencing data. <i>Laboratory Investigation</i> , 2014, 94, 1173-1183.	1.7	2
92	Mismatch Repair Status and <i>BRAF</i> Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. <i>Clinical Cancer Research</i> , 2014, 20, 5322-5330.	3.2	561
93	Towards automatic patient selection for chemotherapy in colorectal cancer trials. <i>Proceedings of SPIE</i> , 2014, , .	0.8	4
94	EURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe. <i>European Journal of Cancer</i> , 2013, 49, 2784-2790.	1.3	76
95	Accurately Identifying Low-Allelic Fraction Variants in Single Samples with Next-Generation Sequencing: Applications in Tumor Subclone Resolution. <i>Human Mutation</i> , 2013, 34, 1432-1438.	1.1	53
96	Sensitive, Simultaneous Quantitation of Two Unlabeled DNA Targets Using a Magnetic Nanoparticle-Enzyme Sandwich Assay. <i>Analytical Chemistry</i> , 2013, 85, 9238-9244.	3.2	35
97	Role of the Oxidative DNA Damage Repair Gene OGG1 in Colorectal Tumorigenesis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1249-1253.	3.0	22
98	Virtual reality microscope versus conventional microscope regarding time to diagnosis: an experimental study. <i>Histopathology</i> , 2013, 62, 351-358.	1.6	34
99	KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 39-46.	1.4	26
100	Mutation Detection by Clonal Sequencing of PCR Amplicons and Grouped Read Typing is Applicable to Clinical Diagnostics. <i>Human Mutation</i> , 2013, 34, 248-254.	1.1	8
101	Ultrasensitive single-nucleotide polymorphism detection using target-recycled ligation, strand displacement and enzymatic amplification. <i>Nanoscale</i> , 2013, 5, 5027.	2.8	48
102	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 749-759.	5.1	333
103	In situ validation of an intestinal stem cell signature in colorectal cancer. <i>Gut</i> , 2013, 62, 1012-1023.	6.1	92
104	Early mortality from colorectal cancer in England: a retrospective observational study of the factors associated with death in the first year after diagnosis. <i>British Journal of Cancer</i> , 2013, 108, 681-685.	2.9	36
105	Chromosome 5q Loss in Colorectal Flat Adenomas. <i>Clinical Cancer Research</i> , 2012, 18, 4560-4569.	3.2	30
106	Prognostic and predictive significance of proliferation in 867 colorectal cancers. <i>Journal of Clinical Pathology</i> , 2012, 65, 989-995.	1.0	9
107	A pictorial description of extralevator abdominoperineal excision for low rectal cancer. <i>Colorectal Disease</i> , 2012, 14, e655-60.	0.7	42
108	Toward Routine Use of 3D Histopathology as a Research Tool. <i>American Journal of Pathology</i> , 2012, 180, 1835-1842.	1.9	128

#	ARTICLE	IF	CITATIONS
109	EnROL: A multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme. <i>BMC Cancer</i> , 2012, 12, 181.	1.1	35
110	Histopathological Work-Up of Resection Specimens, Local Excisions and Biopsies in Colorectal Cancer. <i>Digestive Diseases</i> , 2012, 30, 2-8.	0.8	21
111	Has the new TNM classification for colorectal cancer improved care?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 119-123.	12.5	163
112	Comprehensive Mutation Analysis in Colorectal Flat Adenomas. <i>PLoS ONE</i> , 2012, 7, e41963.	1.1	20
113	T3+ and T4 Rectal Cancer Patients Seem to Benefit From the Addition of Oxaliplatin to the Neoadjuvant Chemoradiation Regimen. <i>Annals of Surgical Oncology</i> , 2012, 19, 392-401.	0.7	24
114	Focus on Extralevator Perineal Dissection in Supine Position for Low Rectal Cancer Has Led to Better Quality of Surgery and Oncologic Outcome. <i>Annals of Surgical Oncology</i> , 2012, 19, 786-793.	0.7	65
115	Comparison of Magnetic Resonance Imaging and Histopathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 2842-2852.	0.7	187
116	Understanding Optimal Colonic Cancer Surgery: Comparison of Japanese D3 Resection and European Complete Mesocolic Excision With Central Vascular Ligation. <i>Journal of Clinical Oncology</i> , 2012, 30, 1763-1769.	0.8	352
117	Working at the microscope: analysis of the activities involved in diagnostic pathology. <i>Histopathology</i> , 2012, 60, 504-510.	1.6	11
118	Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. <i>Colorectal Disease</i> , 2012, 14, 438-444.	0.7	88
119	An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. <i>International Journal of Colorectal Disease</i> , 2012, 27, 233-241.	1.0	250
120	Will Extralevator Abdominoperineal Excision Become the New Gold Standard?. , 2012, , 261-273.		0
121	Value of Mismatch Repair, <i>KRAS</i> , and <i>BRAF</i> Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1261-1270.	0.8	593
122	Mesorectal Fascia Instead of Circumferential Resection Margin in Preoperative Staging of Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2142-2143.	0.8	54
123	MRI Predictive Factors for Long-Term Outcomes of Low Rectal Tumours. <i>Annals of Surgical Oncology</i> , 2011, 18, 3278-3284.	0.7	71
124	Intra-tumoral Heterogeneity of <i>KRAS</i> and <i>BRAF</i> Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing. <i>Analytical Cellular Pathology</i> , 2011, 34, 61-66.	0.7	70
125	Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone. <i>Annals of Surgery</i> , 2011, 253, 711-719.	2.1	524
126	Can a Novel MRI Staging System for Low Rectal Cancer Aid Surgical Planning?. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 1260-1264.	0.7	47

#	ARTICLE	IF	CITATIONS
127	Lymphatic Vessel Distribution in the Mucosa and Submucosa and Potential Implications for T1 Colorectal Tumors. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 35-40.	0.7	40
128	Quality assurance in pathology in colorectal cancer screening and diagnosisâ€”European recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 1-19.	1.4	127
129	Annex to Quirke et al. Quality assurance in pathology in colorectal cancer screening and diagnosis: annotations of colorectal lesions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 21-30.	1.4	26
130	Magnetic Resonance Imagingâ€”Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes: MERCURY Experience. <i>Journal of Clinical Oncology</i> , 2011, 29, 3753-3760.	0.8	557
131	Lymph Nodes, Tumor Deposits, and TNM: Are We Getting Better?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2487-2492.	0.8	120
132	Thirty-day postoperative mortality after colorectal cancer surgery in England. <i>Gut</i> , 2011, 60, 806-813.	6.1	238
133	Validation Study of a Quantitative Multigene Reverse Transcriptaseâ€”Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4611-4619.	0.8	341
134	Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. <i>Analytical Cellular Pathology</i> , 2011, 34, 61-6.	0.7	42
135	Improving the Quality of Colon Cancer Surgery Through a Surgical Education Program. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 1594-1603.	0.7	97
136	Patients With Low Rectal Cancer Treated by Abdominoperineal Excision Have Worse Tumors and Higher Involved Margin Rates Compared With Patients Treated by Anterior Resection. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 53-56.	0.7	104
137	<i>Surgical Pathology</i> . , 2010, , 151-164.		0
138	Complete Mesocolic Excision With Central Vascular Ligation Produces an Oncologically Superior Specimen Compared With Standard Surgery for Carcinoma of the Colon. <i>Journal of Clinical Oncology</i> , 2010, 28, 272-278.	0.8	620
139	Evidence-based medicine: the time has come to set standards for staging. <i>Journal of Pathology</i> , 2010, 221, n/a-n/a.	2.1	44
140	Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. <i>Journal of Pathology</i> , 2010, 221, 411-424.	2.1	39
141	High-Resolution Array Comparative Genomic Hybridization in Sporadic and Celiac Diseaseâ€”Related Small Bowel Adenocarcinomas. <i>Clinical Cancer Research</i> , 2010, 16, 1391-1401.	3.2	64
142	Impact of Short-Course Preoperative Radiotherapy for Rectal Cancer on Patients' Quality of Life: Data From the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group CO16 Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4233-4239.	0.8	196
143	Revised Staging: Is It Really Better, or Do We Not Know?. <i>Journal of Clinical Oncology</i> , 2010, 28, e397-e398.	0.8	18
144	A uniform residual tumor (R) classification. <i>Cancer</i> , 2009, 115, 3483-3488.	2.0	194

#	ARTICLE	IF	CITATIONS
145	Tracking with virtual slides: a tool to study diagnostic error in histopathology. <i>Histopathology</i> , 2009, 55, 37-45.	1.6	36
146	Virtual reality Powerwall versus conventional microscope for viewing pathology slides: an experimental comparison. <i>Histopathology</i> , 2009, 55, 294-300.	1.6	39
147	MRI staging of low rectal cancer. <i>European Radiology</i> , 2009, 19, 643-650.	2.3	104
148	Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 5519-5528.	0.8	120
149	<i>KRAS</i> and <i>BRAF</i> Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 5931-5937.	0.8	517
150	Defining the surgical planes on MRI improves surgery for cancer of the low rectum. <i>Lancet Oncology</i> , The, 2009, 10, 1207-1211.	5.1	66
151	Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. <i>Lancet</i> , The, 2009, 373, 811-820.	6.3	1,292
152	Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG C016 randomised clinical trial. <i>Lancet</i> , The, 2009, 373, 821-828.	6.3	906
153	Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). <i>Radiotherapy and Oncology</i> , 2009, 92, 148-163.	0.3	275
154	Evidence of the Oncologic Superiority of Cylindrical Abdominoperineal Excision for Low Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 3517-3522.	0.8	376
155	What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer?. <i>Journal of Clinical Oncology</i> , 2008, 26, 303-312.	0.8	885
156	Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. <i>Lancet Oncology</i> , The, 2008, 9, 857-865.	5.1	375
157	Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 2690-2698.	0.8	261
158	Molecular markers of chemotherapeutic response and toxicity in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 489-501.	1.1	10
159	Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. <i>Gut</i> , 2007, 56, 1419-1425.	6.1	109
160	Identifying Stage III Colorectal Cancer Patients: The Influence of the Patient, Surgeon, and Pathologist. <i>Journal of Clinical Oncology</i> , 2007, 25, 2573-2579.	0.8	120
161	Randomized Trial of Laparoscopic-Assisted Resection of Colorectal Carcinoma: 3-Year Results of the UK MRC CLASICC Trial Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 3061-3068.	0.8	1,382
162	Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. <i>FEBS Letters</i> , 2007, 581, 1137-1142.	1.3	33

#	ARTICLE	IF	CITATIONS
163	The future of the TNM staging system in colorectal cancer: time for a debate?. <i>Lancet Oncology</i> , The, 2007, 8, 651-657.	5.1	148
164	The Site of the Tumor, Not the Type of Operation, Determines the Worse Prognosis of the Low Rectal Cancer. <i>Annals of Surgery</i> , 2006, 244, 331-332.	2.1	0
165	Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1 Predicts Survival in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1494-1500.	3.2	71
166	Multimodal Imaging Techniques for the Extraction of Detailed Geometrical and Physiological Information for Use in Multi-Scale Models of Colorectal Cancer and Treatment of Individual Patients. <i>Computational and Mathematical Methods in Medicine</i> , 2006, 7, 177-188.	0.7	8
167	The Modern Abdominoperineal Excision. <i>Annals of Surgery</i> , 2005, 242, 74-82.	2.1	384
168	EphB2 is a Prognostic Factor in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5181-5187.	3.2	94
169	Low Rectal Cancer: A Call for a Change of Approach in Abdominoperineal Resection. <i>Journal of Clinical Oncology</i> , 2005, 23, 9257-9264.	0.8	546
170	Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. <i>Lancet</i> , The, 2005, 365, 1718-1726.	6.3	2,854
171	The multidisciplinary rectal cancer treatment: Main convergences, controversial aspects and investigational areas which support the need for an European Consensus. <i>Radiotherapy and Oncology</i> , 2005, 76, 241-250.	0.3	48
172	The role of the pathologist. <i>European Journal of Cancer</i> , Supplement, 2005, 3, 351-359.	2.2	2
173	DNA Methylation, a Biomarker for Colorectal Cancer. <i>Annals of the New York Academy of Sciences</i> , 2003, 983, 251-267.	1.8	30
174	Training and quality assurance for rectal cancer: 20 years of data is enough. <i>Lancet Oncology</i> , The, 2003, 4, 695-702.	5.1	148
175	Macroscopic Evaluation of Rectal Cancer Resection Specimen: Clinical Significance of the Pathologist in Quality Control. <i>Journal of Clinical Oncology</i> , 2002, 20, 1729-1734.	0.8	822
176	Rates of Circumferential Resection Margin Involvement Vary Between Surgeons and Predict Outcomes in Rectal Cancer Surgery. <i>Annals of Surgery</i> , 2002, 235, 449-457.	2.1	591
177	Prediction of the response of colorectal cancer to systemic therapy. <i>Lancet Oncology</i> , The, 2002, 3, 75-82.	5.1	85
178	Biology and genetics of colorectal cancer. <i>European Journal of Cancer</i> , 2001, 37, 163-172.	1.3	10
179	Preface to Genomic Pathology - a New Frontier. <i>Journal of Pathology</i> , 2001, 195, 1-2.	2.1	10
180	A comparison of microsatellite instability in early onset gastric carcinomas from relatively low and high incidence European populations. <i>International Journal of Cancer</i> , 2000, 85, 189-191.	2.3	19

#	ARTICLE	IF	CITATIONS
181	A comparison of microsatellite instability in early onset gastric carcinomas from relatively low and high incidence European populations. <i>International Journal of Cancer</i> , 2000, 85, 189-191.	2.3	5
182	Preimplantation genetic diagnosis using fluorescent polymerase chain reaction: results and future developments. <i>Journal of Assisted Reproduction and Genetics</i> , 1999, 16, 199-206.	1.2	21
183	Rapid trisomy diagnosis (21, 18, and 13) using fluorescent PCR and short tandem repeats: applications for prenatal diagnosis and preimplantation genetic diagnosis. <i>Journal of Assisted Reproduction and Genetics</i> , 1998, 15, 266-275.	1.2	46
184	Comparison of FISH PRINS, and conventional and fluorescent PCR for single-cell sexing: suitability for preimplantation genetic diagnosis. <i>Journal of Assisted Reproduction and Genetics</i> , 1998, 15, 258-265.	1.2	14
185	Prenatal detection of trisomy 13 from amniotic fluid by quantitative fluorescent polymerase chain reaction. <i>Prenatal Diagnosis</i> , 1998, 18, 669-674.	1.1	12
186	Multiple genetic diagnoses from single cells using multiplex PCR: reliability and allele dropout. , 1998, 18, 1413-1421.		44
187	Experimental models of colorectal cancer. <i>Diseases of the Colon and Rectum</i> , 1998, 41, 490-505.	0.7	31
188	Rapid determination of trisomy 18 parental origin using fluorescent PCR and small tandem repeat markers: case reports. <i>Clinical Genetics</i> , 1998, 53, 92-95.	1.0	5
189	Prenatal detection of trisomy 13 from amniotic fluid by quantitative fluorescent polymerase chain reaction. <i>Prenatal Diagnosis</i> , 1998, 18, 669-674.	1.1	3
190	Assessment of microsatellite alterations in young patients with gastric adenocarcinoma. , 1997, 79, 684-687.		28
191	Fluorescent PCR: A new technique for PGD of sex and single-gene defects. <i>Journal of Assisted Reproduction and Genetics</i> , 1996, 13, 96-103.	1.2	59
192	HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER. , 1996, 179, 129-137.		53
193	Antenatal screening for cystic fibrosis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1996, 103, 795-799.	1.1	20
194	HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER. , 1996, 179, 129.		8
195	Microsatellite instability in colorectal cancer: Improved assessment using fluorescent polymerase chain reaction. <i>Gastroenterology</i> , 1995, 109, 465-471.	0.6	94
196	The Pathologist's Role in the Assessment of Local Recurrence in Rectal Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 1992, 1, 1-17.	0.6	52
197	Kaposi's Sarcoma: A Clinico-Pathologic Overview. <i>Tumori</i> , 1991, 77, 291-310.	0.6	4
198	Correlation of morphology, immunophenotype, and flow cytometry with remission induction and survival in high grade non-Hodgkin's lymphoma. <i>Journal of Pathology</i> , 1989, 158, 31-39.	2.1	22

#	ARTICLE	IF	CITATIONS
199	Further applications of the polymerase chain reaction. <i>Journal of Pathology</i> , 1989, 159, 277-279.	2.1	4
200	Flow cytometry of normal, hyperplastic, and malignant human endometrium. <i>American Journal of Obstetrics and Gynecology</i> , 1989, 161, 487-492.	0.7	17
201	Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas. <i>Journal of Pathology</i> , 1987, 151, 285-291.	2.1	181
202	Congenital <i>Torulopsis glabrata</i> Infection in Man. <i>American Journal of Clinical Pathology</i> , 1980, 73, 137-140.	0.4	16
203	Pathology for the radiologist: pathological insights into colorectal cancer. , 0, , 15-33.		0
204	Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	1